青霉烷砜／头孢哌酮与头孢氨噻肟随机对照治疗细菌感染性疾病54例的临床评价

RANDOMIZED CONTROLLED CLINICAL TRIAL ON SULPERAZONE COMPARED WITH CEFOTAXIME

Ｓｕｌｐｅｒａｚｏｎｅ（青霉烷砜与头孢哌酮联合制剂缩写ＳＵＬ）是具有高效抗菌活性的抑酶增效联合制剂。本研究采用开放式随机对照方法评价ＳＵＬ治疗感染性疾患的安全有效性，选用头孢氨噻肟（ＣＴＸ）作为对照药。ＳＵＬ１．０－２．０ｇｉｖｑ１２ｈ；ＣＴＸ１．０－２．０ｇｉｖｑｉｄ。疗程均为７－１４ｄ。２７对呼吸系、泌尿系及皮肤软组织感染患者参加了试验。ＳＵＬ与ＣＴＸ的临床有效率分别为９６．３％和９２．６％；细菌清除率分别为７０．８％和６９．２％；不良反应分别为７．４％和１１．１％。两药间无统计学显著差异。细菌对药物敏感试验结果表明ＳＵＬ是所测药物（头孢氨噻肟、头孢哌酮、安灭菌、ｔｉｍｅｎｔｉｎ）中作用最强的一种，高度敏感菌达９５．９％，与其他所测药物相比有显著的统计学差异，Ｐ值＜０．００１。

Sulperazone(SUL)is a combination of sulbactam(SBT)and cefoperazone(CPZ).A randomized controlled clinical trial on SUL compared with cefotaxime(CTX)was conducted.54 patients with respiratory,urinary,and skin and soft tissue infections were randomized to receive either SUL 1.0-2.0g iv q 12 h or CTX 1.0-2.08 iv qid for 7 to 14 days.The clinical efficacy rates of SUL and CTX were 96.3% and 92.6% respectively.The bacterial clearance rates of them were 70.8% and 69.2% respectively.The adverse drug reactions(ADR)of both groups were mild with the rates of 7.4% and 11.1% respectively Comparison of the susceptibility of clinical isolates to SUL,CPZ,CTX,augmentin and timentin showed that SUL was the most effective antibiotic among them.The rate of susceptibility of clinical isolates to SUL was 95.9%.The difference betwent SUL and other 4 antibioties were significant.The above study showed that SUL is one of the useful drugs in the treatment of infection diseases.